Tirzepatide's Impact on Gastric Emptying in Type 1 Diabetes with Overweight/Obesity Under Investigation

Type 1 Diabetes Mellitus (T1DM) is an autoimmune condition where the pancreas produces little to no insulin, requiring lifelong insulin therapy. While insulin is crucial, many individuals with T1DM also struggle with overweight or obesity, which can exacerbate insulin resistance, increase cardiovascular risk, and complicate glycemic management. Traditional weight loss strategies can be challenging in T1DM due to the risk of hypoglycemia with reduced food intake and the weight-promoting effects of insulin. Gastric emptying plays a critical role in postprandial glucose excursions, as slower emptying can flatten glucose peaks. Understanding how tirzepatide, a dual GLP-1R and GIP-R agonist, impacts gastric emptying in this population could offer novel strategies for improving glycemic control and managing weight without increasing hypoglycemia risk.

This study is designed to investigate the effects of tirzepatide on gastric emptying in participants diagnosed with Type 1 Diabetes Mellitus who also present with overweight or obesity. The study duration is approximately 8 weeks, encompassing initial screening and a follow-up period. The primary objective is to characterize the physiological changes in gastric emptying rates induced by tirzepatide in this specific patient cohort. While specific dosing regimens, participant numbers (n), and detailed control arm information are not provided in this registration record, the study aims to elucidate the mechanisms by which tirzepatide influences gastrointestinal motility in a population where managing both glycemia and weight is complex.